Global programme to eliminate lymphatic filariasis: progress report, 2020

ABSTRACT

This article describes the Global Programme to Eliminate Lymphatic Filariasis (GPELF), which aims to stop the spread of infection by mass drug administration (MDA) and ease the suffering of patients through morbidity management and disability prevention (MMDP). In 2020, LFMDA treated 21.6 million 2-4-year-olds and 98.5 million 5-14-year-olds. Given the impact of LF MDA on soil-transmitted helminth (STH) infections, WHO advises adding STH infection assessment into transmission assessment surveys (TAS) to increase NTD intervention efficiency. Once preTAS and TAS standards are met, an IU's population no longer needs MDA. 692 million people didn't need MDA. This 49% decline in LF cases is a huge step toward meeting the Sustainable Development Goal (SDG). Thirteen countries and 171 IUs performed TASs in 2020. A total of 4316 TAS have been conducted in EUs, which are greater or smaller than IUs. 100% of EUs passed a TAS, according to 2020 reports (the proportion of children who tested positive for LF infection was below the threshold for considering transmission unsustainable). Several 2020 TAS were postponed because to COVID-19 pandemic restrictions. Despite a global epidemic, GPELF achieved progress in 2020, demonstrating the resolve and inventiveness of national LFprogrammes to end this illness.